Ian Pearce1, Sanjiv Banerjee2, Ben J L Burton3, Usha Chakravarthy4, Louise Downey5, Richard P Gale6, Jonathan Gibson7, Sergio Pagliarini8, Jignesh Patel9, Sobha Sivaprasad10, Chris Andrews11, Christopher Brittain12, James Warburton11. 1. St. Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, United Kingdom. Electronic address: ian.pearce@rlbuht.nhs.uk. 2. University Hospital of Wales, Cardiff, United Kingdom. 3. James Paget University Hospital, Great Yarmouth, United Kingdom. 4. Royal Victoria Hospital, Belfast, United Kingdom. 5. Hull and East Yorkshire Eye Hospital, Hull, United Kingdom. 6. York Teaching Hospital, York, United Kingdom. 7. Birmingham Heartlands Hospital, Birmingham, United Kingdom. 8. University Hospitals Coventry & Warwickshire, Hospital of St Cross, Rugby, United Kingdom. 9. Essex County Hospital, Colchester, United Kingdom. 10. Kings College Hospital, London, United Kingdom. 11. Novartis Pharmaceuticals UK Ltd., Surrey, United Kingdom. 12. F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Abstract
PURPOSE: To evaluate ranibizumab 0.5 mg using bimonthly monitoring and individualized re-treatment after monthly follow-up for 6 months in patients with visual impairment due to diabetic macular edema (DME). DESIGN: A phase IIIb, 18-month, prospective, open-label, multicenter, single-arm study in the United Kingdom. PARTICIPANTS: Participants (N = 109) with visual impairment due to DME. METHODS: Participants received 3 initial monthly ranibizumab 0.5 mg injections (day 0 to month 2), followed by individualized best-corrected visual acuity (BCVA) and optical coherence tomography-guided re-treatment with monthly (months 3-5) and subsequent bimonthly follow-up (months 6-18). Laser was allowed after month 6. MAIN OUTCOME MEASURES: Mean change in BCVA from baseline to month 12 (primary end point), mean change in BCVA and central retinal thickness (CRT) from baseline to month 18, gain of ≥10 and ≥15 letters, treatment exposure, and incidence of adverse events over 18 months. RESULTS:Of 109 participants, 100 (91.7%) and 99 (90.8%) completed the 12 and 18 months of the study, respectively. The mean age was 63.7 years, the mean duration of DME was 40 months, and 77.1% of the participants had received prior laser treatment (study eye). At baseline, mean BCVA was 62.9 letters, 20% of patients had a baseline BCVA of >73 letters, and mean baseline CRT was 418.1 μm, with 32% of patients having a baseline CRT <300 μm. The mean change in BCVA from baseline to month 6 was +6.6 letters (95% confidence interval [CI], 4.9-8.3), and after institution of bimonthly treatment the mean change in BCVA at month 12 was +4.8 letters (95% CI, 2.9-6.7; P < 0.001) and +6.5 letters (95% CI, 4.2-8.8) at month 18. The proportion of participants gaining ≥10 and ≥15 letters was 24.8% and 13.8% at month 12 and 34.9% and 19.3% at month 18, respectively. Participants received a mean of 6.8 and 8.5 injections over 12 and 18 months, respectively. No new ocular or nonocular safety findings were observed during the study. CONCLUSIONS: The BCVA gain achieved in the initial 6-month treatment period was maintained with an additional 12 months of bimonthly ranibizumab PRN treatment.
RCT Entities:
PURPOSE: To evaluate ranibizumab 0.5 mg using bimonthly monitoring and individualized re-treatment after monthly follow-up for 6 months in patients with visual impairment due to diabetic macular edema (DME). DESIGN: A phase IIIb, 18-month, prospective, open-label, multicenter, single-arm study in the United Kingdom. PARTICIPANTS: Participants (N = 109) with visual impairment due to DME. METHODS:Participants received 3 initial monthly ranibizumab 0.5 mg injections (day 0 to month 2), followed by individualized best-corrected visual acuity (BCVA) and optical coherence tomography-guided re-treatment with monthly (months 3-5) and subsequent bimonthly follow-up (months 6-18). Laser was allowed after month 6. MAIN OUTCOME MEASURES: Mean change in BCVA from baseline to month 12 (primary end point), mean change in BCVA and central retinal thickness (CRT) from baseline to month 18, gain of ≥10 and ≥15 letters, treatment exposure, and incidence of adverse events over 18 months. RESULTS: Of 109 participants, 100 (91.7%) and 99 (90.8%) completed the 12 and 18 months of the study, respectively. The mean age was 63.7 years, the mean duration of DME was 40 months, and 77.1% of the participants had received prior laser treatment (study eye). At baseline, mean BCVA was 62.9 letters, 20% of patients had a baseline BCVA of >73 letters, and mean baseline CRT was 418.1 μm, with 32% of patients having a baseline CRT <300 μm. The mean change in BCVA from baseline to month 6 was +6.6 letters (95% confidence interval [CI], 4.9-8.3), and after institution of bimonthly treatment the mean change in BCVA at month 12 was +4.8 letters (95% CI, 2.9-6.7; P < 0.001) and +6.5 letters (95% CI, 4.2-8.8) at month 18. The proportion of participants gaining ≥10 and ≥15 letters was 24.8% and 13.8% at month 12 and 34.9% and 19.3% at month 18, respectively. Participants received a mean of 6.8 and 8.5 injections over 12 and 18 months, respectively. No new ocular or nonocular safety findings were observed during the study. CONCLUSIONS: The BCVA gain achieved in the initial 6-month treatment period was maintained with an additional 12 months of bimonthly ranibizumab PRN treatment.
Authors: Andreas Ebneter; Dominik Waldmeier; Denise C Zysset-Burri; Sebastian Wolf; Martin Sebastian Zinkernagel Journal: Graefes Arch Clin Exp Ophthalmol Date: 2016-10-07 Impact factor: 3.117
Authors: Muhammad Z Chauhan; Peyton A Rather; Sajida M Samarah; Abdelrahman M Elhusseiny; Ahmed B Sallam Journal: Cells Date: 2022-06-17 Impact factor: 7.666
Authors: Focke Ziemssen; Patricio G Schlottman; Jennifer I Lim; Hansjürgen Agostini; Gabriele E Lang; Francesco Bandello Journal: Int J Retina Vitreous Date: 2016-07-11
Authors: Christian Prünte; Franck Fajnkuchen; Sajjad Mahmood; Federico Ricci; Katja Hatz; Jan Studnička; Vladimir Bezlyak; Soumil Parikh; William John Stubbings; Andreas Wenzel; João Figueira Journal: Br J Ophthalmol Date: 2015-10-09 Impact factor: 4.638
Authors: Focke Ziemssen; Alan Cruess; Cornelia Dunger-Baldauf; Philippe Margaron; Howard Snow; William David Strain Journal: Eur Endocrinol Date: 2017-08-22